We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+9.27%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$423M
AUM Growth
+$4.74M
Cap. Flow
-$21.3M
Cap. Flow %
-5.03%
Top 10 Hldgs %
48.91%
Holding
89
New
6
Increased
19
Reduced
26
Closed
5
Avg Time Held
10.6 quarters
Top 10 Avg Time Held
6.8 quarters
Top 20 Avg Time Held
11.1 quarters

Top Buys

Rank Stock Value
1
LXEO icon
Lexeo Therapeutics
LXEO
+$2.99M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$1.87M
3
BPMC icon
Blueprint Medicines
BPMC
+$1.69M
4
DAWN icon
Day One Biopharmaceuticals
DAWN
+$1.2M
5
ALLO icon
Allogene Therapeutics
ALLO
+$1.19M

Top Sells

Rank Stock Value
1
MORF icon
Morphic Holding, Inc. Common Stock
MORF
+$7.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.27M
3
VKTX icon
Viking Therapeutics
VKTX
+$3.73M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.69M
5
TSVT icon
2seventy bio
TSVT
+$1.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86%
2 Miscellaneous 14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
XBI icon
1
State Street SPDR S&P Biotech ETF
XBI
$9.69B
$39.7M 9.37%
401,505
-43,500
-10% -$4.27M
2022 Q1
10 quarters
STXS icon
2
Stereotaxis
STXS
$104M
$27.9M 6.59%
13,680,554
– –
2013 Q2
45 quarters
RVMD icon
3
Revolution Medicines
RVMD
$41.8B
$23.5M 5.55%
517,994
+6,100
+1% +$266K
2020 Q4
15 quarters
CYTK icon
4
Cytokinetics
CYTK
$8.77B
$21M 4.97%
398,100
– –
2021 Q3
12 quarters
MRUS icon
5
DELISTED
Merus
MRUS
$20.6M 4.87%
412,573
+3,128
+0.8% +$163K
2021 Q1
14 quarters
ATRC icon
6
AtriCure
ATRC
$2.93B
$18M 4.25%
641,673
+2,500
+0.4% +$61.6K
2013 Q2
45 quarters
IDYA icon
7
IDEAYA Biosciences
IDYA
$3.27B
$14.9M 3.53%
471,410
+49,197
+12% +$1.87M
2020 Q3
16 quarters
IBB icon
8
iShares Biotechnology ETF
IBB
$10.4B
$14.9M 3.53%
102,500
– –
2016 Q4
31 quarters
ASND icon
9
Ascendis Pharma A/S
ASND
$14.8B
$13.4M 3.16%
89,572
+8,600
+11% +$1.16M
2021 Q4
11 quarters
AXGN icon
10
Axogen
AXGN
$2.13B
$13.1M 3.1%
935,894
– –
2021 Q4
11 quarters
BPMC icon
11
DELISTED
Blueprint Medicines
BPMC
$11.3M 2.66%
121,763
+17,000
+16% +$1.69M
2016 Q4
31 quarters
XENE icon
12
Xenon Pharmaceuticals
XENE
$3.27B
$10.8M 2.55%
273,739
– –
2015 Q3
36 quarters
DAWN icon
13
DELISTED
Day One Biopharmaceuticals
DAWN
$10.5M 2.47%
750,363
+83,900
+13% +$1.2M
2023 Q2
5 quarters
SNDX icon
14
Syndax Pharmaceuticals
SNDX
$1.23B
$10.1M 2.4%
526,702
-130,372
-20% -$2.69M
2020 Q2
17 quarters
BHVN icon
15
Biohaven
BHVN
$1.66B
$9.35M 2.21%
187,130
-31,600
-14% -$1.23M
2022 Q3
8 quarters
TNDM icon
16
Tandem Diabetes Care
TNDM
$1.12B
$8.66M 2.05%
204,208
– –
2023 Q2
5 quarters
KALV icon
17
DELISTED
KalVista Pharmaceuticals
KALV
$8.38M 1.98%
723,678
-83,295
-10% -$1.05M
2021 Q1
14 quarters
NBIX icon
18
Neurocrine Biosciences
NBIX
$13.7B
$8.02M 1.89%
69,615
-2,000
-3% -$274K
2016 Q1
34 quarters
KURA icon
19
Kura Oncology
KURA
$857M
$7.98M 1.89%
408,368
-15,132
-4% -$307K
2017 Q3
28 quarters
VKTX icon
20
Viking Therapeutics
VKTX
$3.3B
$7.95M 1.88%
125,616
-63,501
-34% -$3.73M
2018 Q4
23 quarters
EWTX icon
21
Edgewise Therapeutics
EWTX
$4.04B
$6.08M 1.44%
227,906
-62,291
-21% -$1.24M
2022 Q1
10 quarters
URGN icon
22
UroGen Pharma
URGN
$1.86B
$5.83M 1.38%
458,915
-10,085
-2% -$150K
2024 Q2
1 quarter
BCRX icon
23
BioCryst Pharmaceuticals
BCRX
$2.06B
$5.07M 1.2%
667,000
-37,500
-5% -$285K
2022 Q4
7 quarters
DXCM icon
24
DexCom
DXCM
$31.7B
$4.39M 1.04%
65,552
– –
2017 Q3
28 quarters
KROS icon
25
Keros Therapeutics
KROS
$219M
$4.28M 1.01%
73,754
+6,000
+9% +$296K
2022 Q2
9 quarters
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, DAFNA Capital Management held 89 positions worth $423M, up 1.1% from $419M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management withdrew a net $21.3M in Q3 2024, closing 5 positions and reducing 26 holdings. Its most notable exit was Morphic Holding, Inc. Common Stock, an estimated $7.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 86% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in Lexeo Therapeutics worth $2.27M.

  • DAFNA Capital Management's largest Q3 2024 buy was Lexeo Therapeutics: 250,583 shares worth $2.27M.
  • DAFNA Capital Management added most to IDEAYA Biosciences in Q3 2024, an estimated $1.87M increase.
  • DAFNA Capital Management's biggest Q3 2024 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $4.27M.
  • DAFNA Capital Management fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $7.9M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $423M portfolio in Q3 2024.
  • DAFNA Capital Management opened 6 new positions and closed 5 in Q3 2024.
  • DAFNA Capital Management's portfolio value rose 1.1% quarter-over-quarter to $423M.

Based on DAFNA Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.